NYSE:FMS - Fresenius Medical Care AG & Co. KGaA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 17
  • Breakdown:
  • 1 Sell Ratings
  • 10 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$41.48
▼ -0.04 (-0.10%)

This chart shows the closing price for FMS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fresenius Medical Care AG & Co. KGaA Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FMS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FMS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 17 analysts offering 12 month price targets for Fresenius Medical Care AG & Co. KGaA in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $41.48.

This chart shows the closing price for FMS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 17 contributing investment analysts is to hold stock in Fresenius Medical Care AG & Co. KGaA. This rating has held steady since January 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 1 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 1 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 1 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 1 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 9 hold ratings
  • 1 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 10 hold ratings
  • 1 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 10 hold ratings
  • 1 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 10 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/12/2021Nord/LBUpgradeHold ➝ BuyMedium
5/11/2021DZ BankReiterated RatingBuyLow
5/10/2021Credit Suisse GroupReiterated RatingNeutralLow
4/28/2021BarclaysReiterated RatingOverweightLow
3/2/2021Berenberg BankReiterated RatingBuyMedium
2/26/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
2/24/2021TruistDowngradeBuy ➝ HoldLow
2/17/2021UBS GroupReiterated RatingBuyMedium
2/5/2021Berenberg BankReiterated RatingBuyLow
2/4/2021BNP ParibasDowngradeOutperform ➝ NeutralLow
2/4/2021Exane BNP ParibasDowngradeOutperform ➝ NeutralMedium
2/4/2021Kepler Capital MarketsDowngradeBuy ➝ HoldLow
2/4/2021JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
2/3/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldLow
2/3/2021DZ BankReiterated RatingBuyLow
2/3/2021The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyHigh
2/2/2021BarclaysReiterated RatingOverweightLow
2/1/2021Stifel NicolausDowngradeBuy ➝ HoldLow
1/11/2021Jefferies Financial GroupDowngradeHold ➝ UnderperformMedium
1/6/2021Nord/LBReiterated RatingBuyN/A
12/9/2020Morgan StanleyReiterated RatingEqual WeightLow
11/19/2020Royal Bank of CanadaReiterated RatingNeutralLow
11/10/2020Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
11/5/2020UBS GroupReiterated RatingBuyLow
11/4/2020Nord/LBUpgradeHold ➝ BuyLow
10/30/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
10/30/2020Morgan StanleyReiterated RatingEqual WeightLow
10/13/2020Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
9/3/2020JPMorgan Chase & Co.Reiterated RatingBuyHigh
8/18/2020Morgan StanleyReiterated RatingEqual WeightLow
8/13/2020Royal Bank of CanadaReiterated RatingNeutralLow
8/5/2020Jefferies Financial GroupDowngradeBuy ➝ HoldLow
8/3/2020DZ BankReiterated RatingBuyLow
7/28/2020Berenberg BankReiterated RatingBuyLow
7/17/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
6/1/2020BarclaysReiterated RatingOverweightLow
5/21/2020SunTrust BanksBoost Price TargetBuy$46.00 ➝ $48.00Low
5/20/2020Morgan StanleyUpgradeUnderweight ➝ Equal WeightLow
5/19/2020JPMorgan Chase & Co.Reiterated RatingOverweightHigh
5/14/2020Kepler Capital MarketsUpgradeHold ➝ BuyLow
5/11/2020SunTrust BanksBoost Price TargetBuy$42.00 ➝ $46.00Low
5/7/2020DZ BankReiterated RatingBuyLow
4/27/2020BarclaysReiterated RatingOverweightMedium
4/20/2020Royal Bank of CanadaReiterated RatingHold$42.00Low
4/17/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyLow
4/13/2020SunTrust BanksLower Price TargetBuy$46.00 ➝ $42.00Medium
3/23/2020UBS GroupReiterated RatingBuyMedium
3/19/2020DZ BankReiterated RatingBuyMedium
3/3/2020BarclaysReiterated RatingBuyLow
2/25/2020DZ BankReiterated RatingBuyMedium
2/21/2020CfraUpgradeHold ➝ Buy$38.00 ➝ $46.00Low
1/21/2020Jefferies Financial GroupUpgradeHold ➝ Buy$44.50Low
12/6/2019Morgan StanleyDowngradeEqual Weight ➝ UnderweightLow
10/30/2019DZ BankReiterated RatingNeutralLow
10/23/2019Redburn PartnersReiterated RatingBuy ➝ NeutralLow
8/29/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
8/19/2019Royal Bank of CanadaReiterated RatingNeutralLow
8/1/2019BTIG ResearchDowngradeBuy ➝ NeutralLow
7/30/2019DZ BankReiterated RatingNeutralLow
7/11/2019DZ BankReiterated RatingNeutralLow
6/20/2019BarclaysUpgradeEqual Weight ➝ Overweight$40.23Low
6/6/2019Royal Bank of CanadaReiterated RatingNeutralLow
5/9/2019CommerzbankReiterated RatingHold$54.00Low
5/7/2019DZ BankReiterated RatingNeutralLow
3/18/2019Royal Bank of CanadaReiterated RatingNeutralLow
3/5/2019DZ BankReiterated RatingNeutralLow
2/21/2019SunTrust BanksBoost Price TargetBuy ➝ Positive$48.00Low
12/10/2018Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
12/7/2018DZ BankReiterated RatingNeutralLow
11/20/2018SunTrust BanksLower Price TargetBuy$46.00Medium
10/26/2018UBS GroupUpgradeNeutral ➝ Buy$82.00High
10/17/2018DZ BankReiterated RatingBuy ➝ NeutralMedium
10/17/2018Royal Bank of CanadaReiterated RatingNeutralHigh
8/28/2018HSBCUpgradeHold ➝ BuyLow
8/17/2018Royal Bank of CanadaReiterated RatingNeutralLow
8/6/2018DZ BankReiterated RatingBuyLow
7/31/2018Royal Bank of CanadaReiterated RatingNeutralMedium
7/9/2018Bank of AmericaInitiated CoverageBuyLow
7/5/2018Credit Suisse GroupDowngradeOutperform ➝ NeutralLow
5/29/2018Royal Bank of CanadaReiterated RatingNeutralMedium
5/3/2018Royal Bank of CanadaReiterated RatingNeutralLow
4/24/2018Deutsche Bank AktiengesellschaftUpgradeHold ➝ BuyLow
4/23/2018DZ BankReiterated RatingBuyHigh
4/5/2018DZ BankReiterated RatingBuyLow
2/28/2018DZ BankReiterated RatingBuyMedium
2/27/2018Royal Bank of CanadaReiterated RatingNeutralHigh
1/4/2018UBS GroupUpgradeSell ➝ NeutralLow
1/2/2018Nord/LBReiterated RatingBuyLow
12/27/2017Nord/LBReiterated RatingBuyLow
12/21/2017SunTrust BanksSet Price TargetBuy$62.00Low
12/18/2017DZ BankReiterated RatingBuyLow
12/11/2017Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
11/13/2017DZ BankReiterated RatingBuyN/A
9/13/2017Royal Bank of CanadaReiterated RatingHold$44.00Low
8/8/2017Royal Bank of CanadaReiterated RatingNeutral$44.00Low
8/7/2017DZ BankReiterated RatingBuyMedium
8/1/2017Royal Bank of CanadaReiterated RatingNeutralLow
7/5/2017Royal Bank of CanadaReiterated RatingHold$44.00Low
7/4/2017UBS GroupReiterated RatingSellN/A
6/28/2017Nord/LBReiterated RatingBuyLow
5/30/2017Royal Bank of CanadaReiterated RatingHold$44.00High
5/29/2017DZ BankReiterated RatingNeutralLow
5/20/2017DZ BankReiterated RatingNeutralLow
5/11/2017DZ BankReiterated RatingNeutralLow
5/3/2017Royal Bank of CanadaReiterated RatingNeutralMedium
3/21/2017UBS GroupDowngradeBuy ➝ SellN/A
3/12/2017Sanford C. BernsteinReiterated RatingBuyLow
3/7/2017DZ BankReiterated RatingBuyN/A
2/24/2017Societe GeneraleDowngradeBuy ➝ HoldN/A
1/9/2017DZ BankReiterated RatingNeutralN/A
12/14/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
11/17/2016DZ BankReiterated RatingBuyN/A
11/10/2016DZ BankReiterated RatingNeutralN/A
11/1/2016Royal Bank of CanadaReiterated RatingSector Perform$41.00 ➝ $44.00N/A
11/1/2016Royal Bank of CanadaBoost Price TargetSector Perform$41.00 ➝ $44.00N/A
10/18/2016CitigroupReiterated RatingBuyN/A
10/13/2016SunTrust BanksSet Price TargetBuy$48.00N/A
9/21/2016The Goldman Sachs GroupReiterated RatingBuyN/A
9/16/2016DZ BankReiterated RatingNeutralN/A
9/13/2016The Goldman Sachs GroupReiterated RatingBuyN/A
9/6/2016CitigroupUpgradeNeutral ➝ BuyN/A
8/9/2016Berenberg BankReiterated RatingBuyN/A
8/4/2016DZ BankReiterated RatingNeutralN/A
7/8/2016Jefferies Financial GroupUpgradeUnderperform ➝ HoldN/A
(Data available from 6/22/2016 forward)
Fresenius Medical Care AG & Co. KGaA logo
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Read More

Today's Range

Now: $41.48
Low: $41.24
High: $41.51

50 Day Range

MA: $40.14
Low: $37.68
High: $42.13

52 Week Range

Now: $41.48
Low: $33.84
High: $46.55

Volume

287,413 shs

Average Volume

375,221 shs

Market Capitalization

$24.30 billion

P/E Ratio

18.52

Dividend Yield

1.37%

Beta

1.29

Frequently Asked Questions

What sell-side analysts currently cover shares of Fresenius Medical Care AG & Co. KGaA?

The following Wall Street analysts have issued research reports on Fresenius Medical Care AG & Co. KGaA in the last twelve months: Barclays PLC, Berenberg Bank, BNP Paribas, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, DZ Bank AG, Exane BNP Paribas, Jefferies Financial Group Inc., JPMorgan Chase & Co., Kepler Capital Markets, Morgan Stanley, Nord/LB, Royal Bank of Canada, Stifel Nicolaus, The Goldman Sachs Group, Inc., TheStreet, Truist, and UBS Group AG.
View the latest analyst ratings for FMS.

What is the current price target for Fresenius Medical Care AG & Co. KGaA?

0 Wall Street analysts have set twelve-month price targets for Fresenius Medical Care AG & Co. KGaA in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Fresenius Medical Care AG & Co. KGaA in the next year.
View the latest price targets for FMS.

What is the current consensus analyst rating for Fresenius Medical Care AG & Co. KGaA?

Fresenius Medical Care AG & Co. KGaA currently has 1 sell rating, 10 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in FMS, but not buy more shares or sell existing shares.
View the latest ratings for FMS.

What other companies compete with Fresenius Medical Care AG & Co. KGaA?

How do I contact Fresenius Medical Care AG & Co. KGaA's investor relations team?

Fresenius Medical Care AG & Co. KGaA's physical mailing address is ELSE-KROENER STRASSE 1, BAD HOMBURG 2M, 61352. The company's listed phone number is 49-6172-608-2522 and its investor relations email address is [email protected] The official website for Fresenius Medical Care AG & Co. KGaA is www.freseniusmedicalcare.com.